1Section of Critical Care Medicine, University of Manitoba, Winnipeg, MB, Canada.
2Department of Anesthesia, University of Manitoba, Winnipeg, MB, Canada.
3Department of Community Health and Epidemiology, Dalhousie University, Halifax, NS, Canada.
4Departments of Medical Microbiology and Pharmacology/Therapeutics, University of Manitoba, Winnipeg, MB, Canada.
5The Center for Health Evaluation and Outcome Sciences and Department of Medicine (PD), St Paul’s Hospital and University of British Columbia, Vancouver, BC, Canada.
6Department of Surgery and Critical Care Medicine, Keenan Research Centre of the Li Ka Shing Knowledge Institute, St. Michaels Hospital, The University of Toronto, Toronto, ON, Canada.
* See also p. 2442.
Additional members of the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group can be found in Appendix 1. Dr. Kumar had full access to all the data in the study and takes responsibility for the integrity of the database and the accuracy of the data analysis. Dr. Kumar developed this specific research concept and the septic shock database. Dr. Kumar and Mr. Doucette were responsible for the methodological design issues and data analysis. Drs. Funk and Kumar prepared this manuscript. All authors assisted with data interpretation and manuscript revisions.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/ccmjournal).
Supported, in part, by grants from the Health Sciences Centre Foundation, the Deacon Foundation of Winnipeg, and the Manitoba Health Research Council. Additional unrestricted funding was supplied by Astellas, Eli-Lilly, Bayer, Pfizer and Merck. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Dr. Marshall served as board member for Asahi Kasei Pharma America Data Monitoring Committee and consulted for Spectral Diagnostics and the Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic Shock (EUPHRATES) Steering Committee. Dr. Kumar lectured for Pfizer and received support for article research from the Deacon Foundation of Winnipeg, Health Sciences Centre Foundation, and Manitoba Health Research Council. His institution received grant support from Astellas, Eli-Lilly, Bayer, Pfizer, and Merck (unrestricted research grants) and from Roche and GlaxoSmithKline (unrelated studies on H1N1). His institution received grant support from Canadian Institutes of Health Research and Physicians Services Incorporated Foundation. None of the authors have financial or personal relationships or affiliations that could influence (or bias) the decision regarding the analysis or manuscript in any regard. The remaining authors have disclosed that they do not have any potential conflicts of interest.
For information regarding this article, E-mail: [email protected]
